Snchez-Garrido MA, Brandt SJ, Clemmensen C, Mller TD, DiMarchi RD, Tschp MH
Ultimately, they compared the outcomes of roughly 439,000 type 2 diabetes patients taking a GLP-1 with those of a similarly sized group of patients, closely matched in age and other characteristics, taking another medication
This was the first instance of ADA guidelines outlining the use of GLP-1 receptor agonists in patients with T2DM with ASCVD or risk factors for ASCVD
Please think carefully before you post any information via the Services
If you are currently on a medically supervised weight loss program in Lexington, Louisville, or London, KY and have noticed changes in your sex drive, this is what the science says about why it happens and what can be done about it